tirzepatide ncbi Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond The catcher in the gut:

any rapid weight loss, whether from medication or bariatric surgery, can have the same effect

Only one complaint in the last three years, and it was resolved

That open-label extension study is intended to assess the long-term safety and tolerability of simufilam 100 mg twice daily in patients who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials

It ensures that your body adapts slowly, reducing the risk of side effects and improving long-term tolerability

Acknowledgements Medical writing and editorial support were provided by Nicole Cash, PhD, and Abbey Pearson, MSci, of Axis, a division of Spirit Medical Communications Group Limited (and were funded by Novo Nordisk Inc.) in accordance with Good Publication Practice 3 (GPP3) guidelines ( Declarations Funding This trial and medical writing support for the publication were funded by Novo Nordisk A/S, Sborg, Denmark

This raises an interesting question: could PTH be more than an epiphenomenon - perhaps part of a broader neurohumoral and mineral-metabolic axis involved in AF onset, atrial remodelling, and disease progression